CALC CalciMedica, Inc.
Financings ·
CalciMedica filed a prospectus supplement on September 30, 2026 for up to $25,000,000 of stock, sold through H.C. Wainwright & Co., LLC as sales agent for a 3.0% commission. The company has stopped one Phase 2 trial of its lead drug and now plans a Phase 2b step first.
Investors agreed to buy 18,673,429 units at $0.8033 or $0.8032. Series A and B warrants could add up to approximately $34 million if fully exercised for cash. Closing is expected on or about June 25, 2026.
Avenue Venture Opportunities Fund II, L.P. is the lender on a $10,000,000 loan. The amendment moves maturity to September 1, 2029, expands the lender's conversion right to up to $3,000,000 and cuts the warrant price to $1.00.
The Avenue Venture Opportunities Fund II loan matures September 1, 2028 and carries a warrant for 641,163 shares at $2.32. CalciMedica says the first tranche extends its cash runway to the middle of 2026.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $15.2 million | $14.5 million |
| Net income (loss) | -$29.6 million | -$13.7 million |
| Cash from operations | -$21.2 million | -$21.1 million |
| Cash and equivalents | $11.5 million | $7.9 million |
| Short-term investments | $1.5 million | $10.7 million |
Our latest story on this, dated Sep 30, 2026: "CalciMedica files to sell up to $25,000,000 of stock through at-the-market program". The story links the filing or release it is based on. Read the story.
CalciMedica, Inc. trades under the ticker CALC on NASDAQ.
CalciMedica, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for CalciMedica, Inc. is 1534133. Its filings are on SEC EDGAR.
34,141,460 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-11.
Our directory records CalciMedica, Inc. under United States.
Our directory classifies CalciMedica, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for CalciMedica, Inc. is US38942Q3011.
aibio.space lists CalciMedica, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
CalciMedica, Inc. reported a net loss of $29.6 million for the fiscal year ended Dec 31, 2025, and used $21.2 million of cash in operations, per its annual report to the SEC.
$15.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$18.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on CalciMedica, dated Sep 30, 2026: "CalciMedica files to sell up to $25,000,000 of stock through at-the-market program". CalciMedica filed a prospectus supplement on September 30, 2026 for up to $25,000,000 of stock, sold through H.C. Wainwright & Co., LLC as sales agent for a 3.0% commission. The company has stopped one Phase 2 trial of its lead drug and now plans a Phase 2b step first. Source.
Our latest debt story, dated Jun 23, 2026: "CalciMedica pushes Avenue loan maturity to 2029 and cuts warrant price". Avenue Venture Opportunities Fund II, L.P. is the lender on a $10,000,000 loan. The amendment moves maturity to September 1, 2029, expands the lender's conversion right to up to $3,000,000 and cuts the warrant price to $1.00. Source.
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio